Eupraxia Pharmaceuticals (EPRX) furnishes Q3 2025 financials and MD&A in Form 6-K

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The report furnishes consolidated financial statements and management’s discussion and analysis for the three and nine months ended September 30, 2025, along with a November 4, 2025 press release.

The filing also includes interim certification forms signed by the Chief Executive Officer and Chief Financial Officer, and incorporates the attached financial statements and MD&A by reference into the company’s existing Form F-10 and Form S-8 registration statements.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-41923

EUPRAXIA PHARMACEUTICALS INC.

(Translation of registrant’s name into English)

201-2067 Cadboro Bay Road

Victoria, British Columbia, Canada V8R 5G4

Telephone: (250) 590-3968

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐   Form 40-F ☒

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 of this Form 6-K are incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-276586) and the registrant’s Registration Statement on Form S-8 (File No. 333-278534).

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Consolidated Financial Statements for the three and nine months ended September 30, 2025.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2025.
99.3		Press Release, dated November 4, 2025.
99.4		Form 52-109F2 Certification of Interim Filings by CEO.
99.5		Form 52-109F2 Certification of Interim Filings by CFO.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				Eupraxia Pharmaceuticals Inc.
Date: November 4, 2025				By:		/s/ Alex Rothwell
						Name: Alex Rothwell
						Title: Chief Financial Officer

FAQ

What does Eupraxia Pharmaceuticals (EPRX) report in this November 2025 Form 6-K?

Eupraxia Pharmaceuticals Inc. furnishes a Form 6-K that includes consolidated financial statements and management’s discussion and analysis for the three and nine months ended September 30, 2025, plus a related November 4, 2025 press release and officer certifications.

Which periods do Eupraxia Pharmaceuticals (EPRX) financial statements in the 6-K cover?

The Form 6-K includes consolidated financial statements for Eupraxia Pharmaceuticals Inc. covering the three and nine months ended September 30, 2025, together with a management’s discussion and analysis for the same periods.

How is the November 2025 Eupraxia (EPRX) Form 6-K used in existing registrations?

The filing states that Exhibits 99.1 and 99.2 are incorporated by reference into Eupraxia’s Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).

What additional documents are attached to the Eupraxia (EPRX) November 2025 Form 6-K?

Alongside financial statements and MD&A, the 6-K includes a press release dated November 4, 2025 and Form 52-109F2 certifications of interim filings from both the CEO and the CFO.

Who signed the Eupraxia Pharmaceuticals (EPRX) November 2025 Form 6-K?

The Form 6-K is signed on behalf of Eupraxia Pharmaceuticals Inc. by Alex Rothwell, who is identified in the document as the company’s Chief Financial Officer, dated November 4, 2025.

Does Eupraxia Pharmaceuticals (EPRX) indicate its annual SEC report format in this 6-K?

Yes. The Form 6-K indicates whether Eupraxia Pharmaceuticals Inc. files or will file its annual reports under cover of Form 20-F or Form 40-F, reflecting its status as a foreign private issuer.